Last reviewed · How we verify
TQA3605 tablets plus NAs — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
TQA3605 tablets plus NAs (TQA3605 tablets plus NAs) — Chia Tai Tianqing Pharmaceutical Group Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TQA3605 tablets plus NAs TARGET | TQA3605 tablets plus NAs | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TQA3605 tablets plus NAs CI watch — RSS
- TQA3605 tablets plus NAs CI watch — Atom
- TQA3605 tablets plus NAs CI watch — JSON
- TQA3605 tablets plus NAs alone — RSS
Cite this brief
Drug Landscape (2026). TQA3605 tablets plus NAs — Competitive Intelligence Brief. https://druglandscape.com/ci/tqa3605-tablets-plus-nas. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing